Connection

Murray Passo to Arthritis, Juvenile

Back to Details
This is a "connection" page, showing publications Murray Passo has written about Arthritis, Juvenile.
Murray Passo
Connection Strength
4.381
Arthritis, Juvenile
  1. Differences in disease outcomes between medicaid and privately insured children: possible health disparities in juvenile rheumatoid arthritis. Arthritis Rheum. 2006 Jun 15; 55(3):378-84.
    View in: PubMed
    Score: 0.257
  2. Emerging therapies in juvenile rheumatoid/idiopathic arthritis. Curr Probl Pediatr Adolesc Health Care. 2006 Mar; 36(3):97-103.
    View in: PubMed
    Score: 0.252
  3. Social, emotional, and behavioral functioning of children with juvenile rheumatoid arthritis. Arthritis Rheum. 2000 Jun; 43(6):1387-96.
    View in: PubMed
    Score: 0.169
  4. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 2019 06; 71(6):864-877.
    View in: PubMed
    Score: 0.157
  5. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019 06; 71(6):717-734.
    View in: PubMed
    Score: 0.157
  6. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol. 2019 06; 71(6):846-863.
    View in: PubMed
    Score: 0.157
  7. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res (Hoboken). 2019 06; 71(6):703-716.
    View in: PubMed
    Score: 0.157
  8. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis Rheumatol. 2019 03; 71(3):451-459.
    View in: PubMed
    Score: 0.154
  9. The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr. 1999 Jan; 134(1):47-52.
    View in: PubMed
    Score: 0.153
  10. Use of methotrexate in children. Bull Rheum Dis. 1998 Aug; 47(5):1-5.
    View in: PubMed
    Score: 0.149
  11. Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in?Children With Polyarticular Forms of Juvenile Idiopathic?Arthritis With Clinically Inactive Disease. Arthritis Rheumatol. 2018 09; 70(9):1508-1518.
    View in: PubMed
    Score: 0.149
  12. Long-term outcome among patients with juvenile rheumatoid arthritis. Front Biosci. 1998 Mar 21; 3:e13-22.
    View in: PubMed
    Score: 0.145
  13. High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2018 04; 70(4):594-605.
    View in: PubMed
    Score: 0.144
  14. The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1997 Dec; 40(12):2226-34.
    View in: PubMed
    Score: 0.142
  15. Magnetic resonance imaging in juvenile rheumatoid arthritis. Semin Arthritis Rheum. 1997 Dec; 27(3):161-8.
    View in: PubMed
    Score: 0.142
  16. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996 Nov; 129(5):630-2.
    View in: PubMed
    Score: 0.132
  17. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013 May; 65(5):745-52.
    View in: PubMed
    Score: 0.104
  18. Effectiveness of dexamethasone iontophoresis for temporomandibular joint involvement in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011 Nov; 63(11):1511-6.
    View in: PubMed
    Score: 0.093
  19. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011 Jan; 63(1):10-6.
    View in: PubMed
    Score: 0.088
  20. Educational and occupational outcomes among young adults with juvenile idiopathic arthritis. Arthritis Rheum. 2008 Oct 15; 59(10):1385-91.
    View in: PubMed
    Score: 0.076
  21. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008 Sep; 58(9):2892-6.
    View in: PubMed
    Score: 0.075
  22. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007 Mar; 56(3):965-71.
    View in: PubMed
    Score: 0.067
  23. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006 Sep-Oct; 24(5):599-605.
    View in: PubMed
    Score: 0.065
  24. A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis. Arthritis Rheum. 2006 Jul; 54(7):2235-42.
    View in: PubMed
    Score: 0.064
  25. Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. J Clin Rheumatol. 2005 Aug; 11(4):194-204.
    View in: PubMed
    Score: 0.060
  26. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2005 Jan; 52(1):239-46.
    View in: PubMed
    Score: 0.058
  27. Feasibility and construct validity of the parent willingness-to-pay technique for children with juvenile idiopathic arthritis. Arthritis Rheum. 2004 Dec 15; 51(6):899-908.
    View in: PubMed
    Score: 0.058
  28. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther. 2005; 7(1):R30-7.
    View in: PubMed
    Score: 0.058
  29. Gene expression in juvenile arthritis and spondyloarthropathy: pro-angiogenic ELR+ chemokine genes relate to course of arthritis. Rheumatology (Oxford). 2004 Aug; 43(8):973-9.
    View in: PubMed
    Score: 0.056
  30. Brief report: child-rearing practices of caregivers with and without a child with juvenile rheumatoid arthritis: perspectives of caregivers and professionals. J Pediatr Psychol. 2003 Jun; 28(4):275-9.
    View in: PubMed
    Score: 0.052
  31. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003 Mar; 142(3):292-6.
    View in: PubMed
    Score: 0.051
  32. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol. 2003 Feb; 30(2):394-400.
    View in: PubMed
    Score: 0.051
  33. Comparing parental distress, family functioning, and the role of social support for caregivers with and without a child with juvenile rheumatoid arthritis. J Pediatr Psychol. 2003 Jan-Feb; 28(1):5-15.
    View in: PubMed
    Score: 0.051
  34. A controlled longitudinal study of the social functioning of children with juvenile rheumatoid arthritis. J Pediatr Psychol. 2003 Jan-Feb; 28(1):17-28.
    View in: PubMed
    Score: 0.051
  35. Arthritis in childhood. J Indiana State Med Assoc. 1981 Sep; 74(9):559-64.
    View in: PubMed
    Score: 0.046
  36. Chemokine receptor CCR4 on CD4+ T cells in juvenile rheumatoid arthritis synovial fluid defines a subset of cells with increased IL-4:IFN-gamma mRNA ratios. J Immunol. 2001 Jun 01; 166(11):6899-906.
    View in: PubMed
    Score: 0.045
  37. Age-specific effects of juvenile rheumatoid arthritis-associated HLA alleles. Arthritis Rheum. 1999 Sep; 42(9):1843-53.
    View in: PubMed
    Score: 0.040
  38. Substance use among adolescents with juvenile rheumatoid arthritis. Arthritis Care Res. 1998 Oct; 11(5):391-6.
    View in: PubMed
    Score: 0.038
  39. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol. 1998 Jul; 25(7):1388-98.
    View in: PubMed
    Score: 0.037
  40. Comparative sequence analysis of the human T cell receptor beta chain in juvenile rheumatoid arthritis and juvenile spondylarthropathies: evidence for antigenic selection of T cells in the synovium. Arthritis Rheum. 1998 Mar; 41(3):482-97.
    View in: PubMed
    Score: 0.036
  41. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum. 1997 Nov; 40(11):1976-83.
    View in: PubMed
    Score: 0.035
  42. Immunohistological characteristics of T cell infiltrates in different forms of childhood onset chronic arthritis. J Rheumatol. 1996 Dec; 23(12):2116-24.
    View in: PubMed
    Score: 0.033
  43. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum. 1996 Oct; 39(10):1703-10.
    View in: PubMed
    Score: 0.033
  44. Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis. J Rheumatol. 1996 Apr; 23(4):747-52.
    View in: PubMed
    Score: 0.032
  45. Patterns of T lymphocyte clonal expansion in HLA-typed patients with juvenile rheumatoid arthritis. J Rheumatol. 1995 Jul; 22(7):1356-64.
    View in: PubMed
    Score: 0.030
  46. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994 Dec; 21(12):2353-8.
    View in: PubMed
    Score: 0.029
  47. Dominant T-cell-receptor beta chain variable region V beta 14+ clones in juvenile rheumatoid arthritis. Proc Natl Acad Sci U S A. 1993 Dec 01; 90(23):11104-8.
    View in: PubMed
    Score: 0.027
  48. Human leukocyte antigen-DRB1*1104 in the chronic iridocyclitis of pauciarticular juvenile rheumatoid arthritis. J Pediatr. 1992 Jul; 121(1):56-60.
    View in: PubMed
    Score: 0.024
  49. The iridocyclitis of early onset pauciarticular juvenile rheumatoid arthritis: outcome in immunogenetically characterized patients. J Rheumatol. 1992 Jan; 19(1):160-3.
    View in: PubMed
    Score: 0.024
  50. Longitudinal analysis of HLA associated risks for iridocyclitis in juvenile rheumatoid arthritis. J Rheumatol. 1991 Sep; 18(9):1394-7.
    View in: PubMed
    Score: 0.023
  51. Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. J Pediatr. 1990 Oct; 117(4):645-52.
    View in: PubMed
    Score: 0.022
  52. School problems and teacher responsibilities in juvenile rheumatoid arthritis. J Sch Health. 1987 May; 57(5):186-90.
    View in: PubMed
    Score: 0.017
  53. The child with arthritis in the school setting. Pediatr Clin North Am. 1986 Oct; 33(5):1251-64.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.